WHITEGLOVEMD
Powered by Clintelligence™ AI
The choice between TAVR (transcatheter aortic valve replacement) and SAVR (surgical aortic valve replacement) is one of the most consequential decisions in cardiac surgery. Both procedures replace a diseased aortic valve, but through fundamentally different approaches. TAVR delivers a new valve via catheter without opening the chest, while SAVR requires a sternotomy and cardiopulmonary bypass. The PARTNER and Evolut clinical trial programs have expanded TAVR from high-risk patients to all risk categories, fundamentally changing the treatment landscape. However, the choice is not simply "newer is better" — it depends on patient age, anatomy, valve morphology, life expectancy, and personal preferences.
TAVR delivers a new bioprosthetic valve inside the diseased valve via a catheter, most commonly through the femoral artery. The procedure typically takes 1-2 hours and does not require a sternotomy or cardiopulmonary bypass. Patients are often awake with conscious sedation rather than general anesthesia.
SAVR removes the diseased aortic valve and replaces it with a mechanical or bioprosthetic valve through a sternotomy. The procedure uses cardiopulmonary bypass and typically takes 3-4 hours. It has been the gold standard for aortic valve disease for over 60 years with extensive long-term outcome data.
The 2020 ACC/AHA Guidelines for Valvular Heart Disease recommend shared decision-making with a Heart Team for patients with severe aortic stenosis. For patients over 80, TAVR is preferred (Class I). For patients under 65, surgical AVR is preferred (Class I). For ages 65-80, the choice should be individualized based on anatomy, comorbidities, and patient preferences (Class I for both). The guidelines emphasize that valve durability, need for concomitant procedures, and patient life expectancy should guide the decision.
The Heart Team approach is essential for the TAVR vs SAVR decision because it requires both surgical and interventional perspectives. A cardiac surgeon evaluates surgical candidacy, anatomy, and the potential for concomitant procedures. An interventional cardiologist evaluates catheter-based approach feasibility, vascular access, and valve sizing. WhiteGloveMD provides this dual-perspective evaluation for every aortic stenosis patient.
TAVR and SAVR are both excellent options with high success rates. The optimal choice depends on patient age, anatomy (particularly bicuspid vs trileaflet), need for concomitant procedures, life expectancy, and personal preferences. Younger patients generally benefit from surgical AVR for durability; older or higher-risk patients generally benefit from TAVR for faster recovery. A Heart Team evaluation is the best way to determine the optimal approach for your specific situation.
TAVR has lower short-term morbidity and faster recovery. However, it has higher rates of pacemaker implantation and paravalvular leak. Overall 30-day mortality is similar for low and intermediate-risk patients. Safety depends on individual patient factors.
Current data shows excellent TAVR valve function at 5-7 years. Long-term data beyond 10 years is limited because TAVR is relatively new. Surgical bioprosthetic valves have 15-20 year track records. This durability question is particularly important for younger patients.
TAVR is FDA-approved for bicuspid valves, but outcomes may be less predictable due to asymmetric anatomy. Surgical AVR generally provides more reliable results for bicuspid valves. The decision should be individualized with Heart Team input.
Valve-in-valve TAVR (placing a new TAVR valve inside the old one) is an option for failing TAVR valves, avoiding redo surgery. However, the initial TAVR valve size can limit this option. Surgical replacement is also possible after TAVR.
Our Heart Team evaluates your specific anatomy, risk factors, and goals to recommend the best approach. 48-hour turnaround.